Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of ICA 17043 in Sickle Cell Disease
2006-001652-12Phase 3
- Sponsor
- Icagen
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of senicapoc in sickle cell disease (SCD) (2 arms), sponsored by Icagen. Primary endpoint: Long-term safety monitoring of ICA 17043 with or without hydroxyurea.
02
Drugs
senicapoc
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2006-001652-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001652-12.